A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Charles D Blanke; Nora C Mattek; Thomas G Deloughery; Dennis R Koop

doi:10.1016/j.prostaglandins.2004.10.004

A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Prostaglandins Other Lipid Mediat. 2005 Jan;75(1-4):169-72. doi: 10.1016/j.prostaglandins.2004.10.004.

Authors

Charles D Blanke¹, Nora C Mattek, Thomas G Deloughery, Dennis R Koop

Affiliation

¹ Oregon Health and Science University Cancer Institute, Portland, OR, USA. blankec@ohsu.edu

PMID: 15789623
DOI: 10.1016/j.prostaglandins.2004.10.004

Abstract

A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.

Publication types

Clinical Trial
Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Abdominal Pain
Antineoplastic Combined Chemotherapy Protocols / toxicity*
Celecoxib
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
Cyclooxygenase Inhibitors / administration & dosage
Diarrhea
Drug Administration Schedule
Fluorouracil / administration & dosage
Humans
Leucovorin / administration & dosage
Pyrazoles / administration & dosage
Sulfonamides / administration & dosage

Substances

Cyclooxygenase Inhibitors
Pyrazoles
Sulfonamides
Celecoxib
Leucovorin
Fluorouracil